0 products, total $0.+86-400-890-9989      Login |  Register 中文한국어

Browse By Molecule:

Your Position: Home > Antibody > Rabbit PAb Antibody > SOD2 Antibody (Antigen Affinity Purified)

SOD2 Antibody (Antigen Affinity Purified) PDF Download

Catalog Size (Price) Quantity In Stock Operation Other Information
12656-RP02
  YES          

SOD2 Antibody ( Antigen Affinity Purified ) Datasheet

  Order or Inquire for SOD2 Antibody product Antibody
  Detection limit is 0.5 ng/lane in WB
  Detection limit is 0.00975 ng/well in ELISA
 

SOD2 Antibody Product Information

Immunogen :

Recombinant Human SOD2 protein (Catalog#12656-HNAE)

Antibody Type : Rabbit Polyclonal Antibody ( Antibody Purification Platform )
Ig Type :

Rabbit IgG

Formulation : 0.2 μm filtered solution in PBS with 5% trehalose
Preparation :

Produced in rabbits immunized with purified, recombinant Human SOD2 (rh SOD2; Catalog#12656-HNAE; P04179-1; Lys 25-Lys 222). SOD2 specific IgG was purified by Human SOD2 affinity chromatography.

SOD2 Antibody Usage Guide

Specificity :

Human SOD2

Immunochemistry :

IHC-P: 0.1-2 μg/mL

 

SOD2-kidney immunohistochemistry    SOD2-colon-carcinoma immunohistochemistry

Immunochemical staining of human SOD2 in human kidney with rabbit polyclonal antibody (1 µg/mL, formalin-fixed paraffin embedded sections). Immunochemical staining of human SOD2 in human colon carcinoma with rabbit polyclonal antibody (1 µg/mL, formalin-fixed paraffin embedded sections).

 

SOD2-placenta immunohistochemistry    

Immunochemical staining of human SOD2 in human placenta with rabbit polyclonal antibody (1 µg/mL, formalin-fixed paraffin embedded sections).
Western blot : This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human SOD2 in WB. Using a DAB detection system, the detection limit for Human SOD2 is approximately 0.5 ng/lane under non-reducing conditions and reducing conditions.
Direct ELISA : This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human SOD2. The detection limit for Human SOD2 is approximately 0.00975 ng/well.
Storage : This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

SOD2 Antibody Related Products & Topics

Related Areas:

Proteins:

Antibodies:

SOD2 Antibody Background

Superoxide dismutases (SOD) are an ubiquitous family of enzymes that function to efficiently catalyze the dismutation of superoxide anions. Three unique and highly compartmentalized mammalian superoxide dismutases have been biochemically and molecularly characterized to date. SOD2, or Mn-SOD, exists as a tetramer and is initially synthesized containing a leader peptide, which targets this manganese-containing enzyme exclusively to the mitochondrial spaces. SOD2 is a member of the iron/manganese superoxide dismutase family. The SOD2 protein transforms toxic superoxide, a byproduct of the mitochondrial electron transport chain, into hydrogen peroxide and diatomic oxygen. In the case of mitochondrial MnSOD of eukaryotes (SOD2), metal insertion cannot occur post-translationally, but requires new synthesis and mitochondrial import of the SOD2 polypeptide. SOD2 can also bind iron in vivo, but is inactive with iron. Such metal ion mis-incorporation with SOD2 can become prevalent upon disruption of mitochondrial metal homeostasis. It is believed that oxidative stress plays an essential role in the development of breast cancer, while SOD2 is one of the primary enzymes that directly convert potential harmful oxidizing species to harmless metabolites. SOD2 Val16Ala polymorphism is not associated with breast cancer susceptibility.

References

  1. Zelko IN. et al., 2002, Free Radic Biol Med. 33 (3): 337-49.
  2. Culotta VC. et al., 2006, Biochim Biophys Acta. 1763 (7): 747-58.
  3. Ma X. et al., 2010, Breast Cancer Res Treat. 122 (2): 509-14.